chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I started to have a mild cough and an itchy throat. That night I started to sneeze and I felt like I had a cold. I had a low grade fever and chills. The next day I felt very tired and I had a runny nose. I lost my sense of smell on the third day. I was very weak and fatigued. I felt better after a week, but it took 3-4 weeks before my sense of smell returned. At the end of the second week, I was unable to take deep full breaths and my cough returned. I was prescribed an inhaler and a Z-pac. It did not help much and I felt bad. I stopped taking the medication and I felt better. On the third week I felt much better with only brief spells of coughing.
This spontaneous report was received from a pharmacist referring to a 21 year old male patient. No information about the patient's medical history, concurrent conditions or concomitant medications was provided. On 19-OCT-2017, 3 months and 2 days after onset of therapy, the patient was vaccinated with the second dose of GARDASIL 9, (lot # N015089 with an expiration date in 20-OCT-2017), intramuscular, for prophylaxis (dose was not provided). No adverse effects were reported.
My period got messed up. I got less bleeding for 1 day. Period stopped then bleeded heavily. It lasted for 2 periods after vaccine. I am better now  Also first months after vaccine.. I was out of energy and so sleepy all the time
This spontaneous report as received from a nurse refers to a 11 year old patient of unknown gender. The patient's medical history and drug reactions were not reported. On 09-APR-2013 the 11 year old patient was vaccinated with a dose of ZOSTAVAX (lot# H010447 as reported is an invalid lot number for zoster vaccine live) (expiration date, dose, route were unknown). Other concomitant medications were not reported. No adverse effects were reported. Additional information has been requested.
Expired Havrix administered; This case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a patient who received HAV (Havrix) (batch number unknown, expiry date 9th August 2022) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 14th September 2022, the patient received Havrix and Havrix Pre-Filled Syringe Device. On 14th September 2022, unknown after receiving Havrix and Havrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 14-Sept-2022 Reporter's comment: The reporter consented to follow-up. Additional supportive information: The patient received an expired dose of Havrix on the day of reporting, which led to expired vaccine used.
Red, hot, itchy, no pain area on left upper arm (triceps area) where Varicella was given.
Pt. c/o red, itchy eyes, dry cough, says "I don't feel good".  Pt. given BENADRYL .32ml IM with relief of symptoms & no further c/o.
"Pt showed episode of vertigo, diaphoresis and hypertension approximately 14 minuites post receiving 1st dose of Moderna COVID-19 vaccine." "Pt was treated on site w/ 12-lead, IV and fluids. Pt refused transport AMA." Site Supervisor Report  **pt did not show up for second dose on 3/27/2021
I had mild flu-like symptoms involving malaise, slight fever (99.4F), nausea and diarrhea lasting about two days. I did call my doctor. I had no specific treatment other than bed rest and as much fluid as I could hold down. This is the second day of this event and I appear to be recovering slowly.
Patient blood pressure elevated for about 3 days. Diastolic usually 80 went up to 110 at one point. After 3 days, BP returned to normal.
Apx 12 hrs after booster, Increasing difused swelling to the left armpit and pectoral area... no lymphnode felt.  The area is sore.  Bumpy rash on both forearms starting 24hrs after booster.
Information has been received from a physician via Company representative concerning to a patient of unknown age and gender. Concurrent and historical conditions were no reported. Concomitant therapies were reported. On 11-JUN-2015, the patient was vaccinated with an improperly stored dose GARDASIL "10x1 sdv" (Lot No. K001631, exp. 06-NOV-2016) (dose and site not reported ). The vaccine status was reported as " in excursion". The vaccine storage criteria and type were reported as "refrigerator (R)". No adverse effects were reported. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a nurse concerning a 25 year old female who on 14-MAR-2008 was vaccinated IM with her first dose of GARDASIL and post vaccination, unknown when, the patient developed numbness of the hands and feet, which lasted for a couple of days. The patient vaccinated IM with her second dose of GARDASIL on 14-MAY-2008 and post vaccination developed numbness of hands and feet which lasted for a couple of days. Subsequently, the patient recovered. The patient sought medical attention and the nurse called her. Additional information has been requested.
A plethora of irritating symptoms: Aching feet, hands, toes, fingers; muscle aches and soreness in various areas, not necessarily all at the same time; stiff and painful right middle finger when waking  in AM, which is painful to straighten out; burning sensations in various areas, again not necessarily all at the same time; skin sensitive, as when putting on pants; fasciculations in various areas, especially left hand where thumb and index finger meet; tingling sensations in arms and legs; transitory sensations of weakness in legs and arms, like when an arm or leg partially "falls asleep" or as if pressure is being applied to a "soft spot" in the armpit.
Initial report was received 22 April 2008 from a health care professional.  A 36-year-old female patient with a history of a codeine allergy, had received a subcutaneous right deltoid injection of YF VAX, lot number UF303AA on 27 March 2008 and 24 hours later, she developed a sore throat.  On 10 April 2008, the patient contacted the travel clinic where she was vaccinated to report that the soreness in her throat had not resolved.  The patient was referred to her primary care physician for follow-up and on 22 April 2008, the patient contacted the travel clinic to report that she had been diagnosed with thyroiditis.  Thyroid function and thyroid level testing was performed (results not reported).  At the time of the report, the patient had not recovered from the event.
5 YO patient received SHINGRIX; received SHINGRIX instead of KINRIX; soreness at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 5-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 4th August 2022, the patient received Shingrix. On 4th August 2022, unknown after receiving Shingrix, the patient experienced inappropriate age at vaccine administration and wrong vaccine administered. In August 2022, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was not recovered/not resolved and the outcome of the inappropriate age at vaccine administration and wrong vaccine administered were unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.     Additional Information: GSK receipt date:05-AUG- 2022 Reporters comment: The reporter was the patient's mother. 5 year old female patient who accidently received SHINGRIX instead of KINRIX.  The reporter also stated that the patient had soreness at the injection site.  The reporter did not consent for follow-up. Additional Supportive information: The patient accidently received SHINGRIX instead of KINRIX, which led to wrong vaccine administered and inappropriate age at vaccination.
Site: Bruising at Injection Site-Mild, Site: Pain at Injection Site-Medium, Systemic: Nausea-Mild, Systemic: Swollen Lymph nodes in armpit-Medium; symptoms lasted 6 days
woke up and feels disorientated,; walking around and feel a little dizzy; pain the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain the injection site), DISORIENTATION (woke up and feels disorientated,) and DIZZINESS (walking around and feel a little dizzy) in an 85-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     Concomitant products included FINASTERIDE, LISINOPRIL and BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) for an unknown indication.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, the patient experienced VACCINATION SITE PAIN (pain the injection site). On 10-Feb-2021, the patient experienced DISORIENTATION (woke up and feels disorientated,) and DIZZINESS (walking around and feel a little dizzy). At the time of the report, VACCINATION SITE PAIN (pain the injection site), DISORIENTATION (woke up and feels disorientated,) and DIZZINESS (walking around and feel a little dizzy) outcome was unknown. Not Provided    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   No treatment details included.
She developed shingles; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer or other non hcp (patient herself) reported that a female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, batch/lot number, and expiration date not reported), via an unspecified route of administration on 23Feb2021, as first dose, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient developed shingles on 01Mar2021. Patient was supposed to have her next dose on 16Mar2021. The outcome of event reported was unknown.  Information on the lot/ batch number has been requested.
eczema- like symptoms in her: ear / eyes / mouth / nose.; She experienced a rash; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 27-Jun-2021 and was forwarded to Moderna on 27-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (eczema- like symptoms in her: ear / eyes / mouth / nose.) and RASH (She experienced a rash) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034C21A) for COVID-19 vaccination.     Concurrent medical conditions included Hyperthyroidism (She does not have any medications but does have hyperthyroidism at baseline).    On 18-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jun-2021, the patient experienced ECZEMA (eczema- like symptoms in her: ear / eyes / mouth / nose.) and RASH (She experienced a rash). At the time of the report, ECZEMA (eczema- like symptoms in her: ear / eyes / mouth / nose.) and RASH (She experienced a rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.
Side effects with first dose were negligible. The second dose given on date specified on this report were more pronounced. Including, fever 100.1., muscle aches, fatigue, headache, nausea and injection site discomfort.
This spontaneous report was received from a Community Nursing Services and refers to a patient of unknown age. On an unknown date the patient was vaccinated with PROQUAD (Merck) lot # H021358, expiry date 29-MAY-2014. Dosing information and route of administration were not provided. The PROQUAD (Merck) vaccine had been stored improperly. Follow up information has been received from a Registered Nurse, who stated that the doses of PROQUAD (Merck) lot # H021358, expiration date on 29-MAY-2014 were exposed to unknown temperature for 5 hours during interoffice transport. All vaccines were unsupported and were possibly administered to patients. No adverse symptoms reported. Nurse was unable to provide further temperature excursion details or dates of administration. All patients were revaccinated. No symptoms were reported. This is one of the several reports from the same source. Additional information is not expected.
Extreme pain in upper right arm and under right arm from armpit area to just under right breast, tired, headache, slight nausea, slight confusion Have taken Tylenol and Ibuprofen, bed rest with very little relief Called physician reported side effects
Information has been received from a consumer concerning her now 14-year-old daughter who in 2000 was vaccinated with her fourth dose of Recombivax HB, previous doses were received at birth, two months, and one year of age. Subsequently, the patient experienced learning disability (onset date not provided) which was considered to be disabling. No additional information is available. There was no product quality complaint. Additional information has been requested.
Pt described pain and felt like arm and left side of body was swelling. Then joint pain. Gave 50mg Benadryl IM at 5pm at 6pm swelling better just joint pain.  Patient did not want to go to ER. Gave pt Benadryl to take home if needed.  Advised to call 911 if any issues with throat swelling or trouble breathing.
pt recvd vax 21APR93; following the vax pt exp a local react manifested by redness, swelling, heat & soreness; pt recovered; No further details were provided;
16 year old received Moderna vaccine; Vaccine given off label; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old received Moderna vaccine) and OFF LABEL USE (Vaccine given off label) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old received Moderna vaccine) and OFF LABEL USE (Vaccine given off label). On 27-Apr-2021, OFF LABEL USE (Vaccine given off label) had resolved. On 25-May-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old received Moderna vaccine) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment information was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: Additional information received on 03-JUN-2021 contains Significant follow up: Added Patient Demographics, Suspect Drug Details (Onset date, 2nd Dose date), Vaccination facility Details, New Event Term Added.
Soreness at the injection site; Injection site was red; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 78-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 5th September 2019, the patient received the 1st dose of Shingrix. On 6th September 2019, 1 days after receiving Shingrix, the patient experienced injection site pain. In September 2019, the patient experienced injection site erythema. On an unknown date, the outcome of the injection site pain was recovering/resolving and the outcome of the injection site erythema was recovered/resolved.   It was unknown if the reporter considered the injection site pain and injection site erythema to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and developed soreness at the injection site. Also, the injection site was red and the redness extended approximately three inches down from the injection site. She said that at the time of reporting the redness was almost gone. Her arm was still sore, but it was less sore than it was initially. The reporter consented to follow up. The reporter gave permission for her physician to be contacted.
This spontaneous report as received from a physician refers to a 2 month old patient of unknown gender. On an unknown date at age of 2 months, the patient was vaccinated with a first dose of ROTATEQ (oral, dose, lot# and expiration date were not reported), then "spit up" the dose. Patient's parents declined to continue the series at that time. The reporter stated that the patient was then inadvertently administered a second dose of ROTATEQ at age 15 months on an unspecified date. It could not be clarified whether any additional adverse effect occurred following this second administration. The outcome of the event of "spit up" the dose was unknown. The relatedness between the event of "spit up" the dose and ROTATEQ was not reported. No PQC (product quality complaint) was involved. Additional information has been requested.
This is a spontaneous report from a contactable consumer (patient). A 62-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiration date were not reported), intramuscularly in right arm on 27Apr2021 at 11:30 (at the age of 62-years-old), 2nd dose, single, for COVID-19 immunization. Medical history included anaphylactic allergies to peanuts and all its products. Concomitant medication included unspecified vitamins. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiration date were not reported) administered intramuscularly on 06Apr2021 at 11:30, 1st dose, single for COVID-19 immunization. Prior to vaccination, the patient was not diagnosed with COVID-19, did not receive other vaccines four weeks prior. The patient was not pregnant at the time of vaccination. The vaccine was administered at hospital. On 28Apr2021 at 00:00, the patient felt like there was a 6 to 8-inch-wide rubber band that was too small and tight around her knees, wrists, elbows, ankles, and feet. The patient had a lot of pain in all joint areas, in between each joint there were waves of being extremely achy and there were waves of a tingling feeling, for example like when the foot falls asleep. The patient reported that the pain was so much, and she just laid still in bed the next 20 hours without moving much. On 29Apr2021, the following day after the pain, the patient was just wrenched and exhausted. The patient had a big stuffy and achy in the head area. On 18May2021, at night the patient felt every sensation came back, but not as severe as earlier. The events were reported as non-serious. No treatment was received for the events. The patient had not been tested for COVID-19 since vaccination. The outcome of the events was not recovered. Information on the lot/batch number has been requested.
HYPOTENSION 2/17/2023 &  2/16/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
I initially started to have these symptoms after dose 3 of the vaccine which I was getting better after taking Tylenol. The symptoms returned along with fatigue and a lot of pain in my shoulder. I contacted the doctor who did an MRI and a CT scan in October of 2022. There was no finding, so they referred me to an ENT who gave me anti-allergy medicine which he prescribed. It was not helpful. I plan to readdress the symptoms at that time. There has been no improvement in the symptoms.
Got the shingles shot ASAP!! I had a mild case & still had it/ Suspected vaccination failure; So painful!!; I had a mild case & still had it; This case was reported by a consumer viainteractive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had shingles once about 20 years ago from reporting date).   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure and pain were unknown and the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine.  Additional details were provided as follows: The case was self-reported by the patient. The age at vaccination was not reported. The reporter stated that, he/she never knew that he/she could get shingles again either until he/she spoke to the doctor. The reporter had the Shingles shot and had a mild case and still had shingles for almost 3 months, was painful. The reporter suggested on definitely checking on getting the shot. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.
This spontaneous report was received from a health professional referring to unspecified patients of unknown age and gender. The patients' medical histories, concurrent conditions and concomitant medication were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of PEDVAXHIB (dose and route of administration were not reported) (Lot# L030871, expiration date 10-JUN-2018; Lot# L035880, expiration date 11-AUG-2018). No adverse effects reported. There was no product quality complaint (PQC) involved. This is one of two reports from the same source (1603USA5084). Additional information has been requested.